Early is Good Receives NIH Phase 2 grant to develop innovative bladder cancer monitoring test (360Dx)
" Early is Good (EIG)...has received a National Institutes of Health (NIH) Phase 2 grant of $1.6M in non-dilutive funding to support validation efforts of its bladder cancer monitoring test, BCDx. This non-invasive urine test is the first multi-omic test, making it a more accurate, affordable, and patient-friendly way to monitor bladder cancer recurrence."